In vitro and in vivo studies have found that XIST promotes the progression of osteosarcoma, and its mechanisms include promoting Rab16 expression by binding miR-758, promoting SNAI1 expression by binding miR-153, and inhibiting NF-κB/PUMA signal can further antagonize apoptosis and mediate the regulation of AGO2 expression by HuR [18–21]. Here, XIST is linked to osteosarcoma.